Skip to main content

Lymphopenia

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

NeoImmuneTech
NeoImmuneTechMD - Rockville
1 program
1
Laboratory Biomarker AnalysisPhase 11 trial
Active Trials
NCT02659800Terminated12Est. Oct 2023
ImmunityBio
ImmunityBioSAN DIEGO, CA
1 program
nogapendekin-alfa inbakiceptN/A1 trial
Active Trials
NCT06956547Available

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NeoImmuneTechLaboratory Biomarker Analysis

Clinical Trials (2)

Total enrollment: 12 patients across 2 trials

NCT02659800NeoImmuneTechLaboratory Biomarker Analysis

Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas

Start: Oct 2018Est. completion: Oct 202312 patients
Phase 1Terminated
NCT06956547ImmunityBionogapendekin-alfa inbakicept

Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy

N/AAvailable

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.